Biotech | October 11, 2021
Astra’s antibody injection trial indicates it can prevent and treat Covid-19
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Subscribe To Our Newsletter & Stay Updated
